Literature DB >> 7771426

Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers.

B H Jaup1, A Norrby.   

Abstract

OBJECTIVES: The aim of this study was to confirm the efficacy and tolerability of a new, low dose, short-term triple therapy for cure of Helicobacter pylori infection, as suggested by Bazzoli, in a larger population.
METHODS: On an "intention-to-treat" basis, 116 patients with active (n = 41) or healed (n = 47) peptic ulcer disease or ulcer-like dyspepsia (n = 28) and H. pylori infection received a 1-wk course of omeprazole 20 mg b.i.d., clarythromycin 250 mg b.i.d., and tinidazole 500 mg b.i.d.. Four weeks after treatment withdrawal, cure of H. pylori infection was evaluated by rapid urease test and histology.
RESULTS: One hundred and sixteen patients returned for follow-up. In 108 patients, H. pylori could not be identified 4 wk after cessation of therapy. The eradication rate was calculated to 93%. In addition, all patients with active peptic ulcers showed complete healing at follow-up despite no further treatment. Drug acceptance and compliance was excellent.
CONCLUSION: Triple therapy as suggested by Bazzoli with omeprazole (in this study given b.i.d. for better compliance), clarythromycin, and tinidazole is indeed highly effective for both cure of H. pylori infection and for healing of peptic ulcers, is easy to perform, is cheap, and is without clinically significant side effects, even in a larger population.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7771426

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

Review 1.  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

Authors: 
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

2.  Treating Helicobacter pylori--the best is yet to come?

Authors:  A Harris; J J Misiewicz
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

3.  Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients.

Authors:  K Hultén; A Gibreel; O Sköld; L Engstrand
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 4.  Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders.

Authors:  A Markham; D McTavish
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives.

Authors:  G R Tennvall; A Norinder; B Ohlin
Journal:  Pharmacoeconomics       Date:  1999-09       Impact factor: 4.981

Review 6.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

7.  New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms.

Authors:  K Hultén; R Rigo; I Gustafsson; L Engstrand
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 8.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 9.  Helicobacter pylori: Emergence of a Superbug.

Authors:  Amin Talebi Bezmin Abadi
Journal:  Front Med (Lausanne)       Date:  2014-10-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.